Research Topics
Species | YOGISH C contact KUDVASummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The effect of walking on postprandial glycemic excursion in patients with type 1 diabetes and healthy peopleChinmay Manohar
Corresponding author Yogish C Kudva
Diabetes Care 35:2493-9. 2012..001). CONCLUSIONS Walking significantly impacts postprandial glucose excursions in healthy populations and in those with type 1 diabetes. AEP algorithms incorporating PA may enhance tight glycemic control end points...- Successful disease-specific induced pluripotent stem cell generation from patients with kidney transplantationTayaramma Thatava
Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
Stem Cell Res Ther 2:48. 2011..Induced pluripotent stem (iPS) cell technology, which allows derivation of patient-specific pluripotent stem cells, could provide a possible alternative modality for kidney replacement therapy for patients with ESRD... - Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cellsSeiga Ohmine
Department of Molecular Medicine, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Stem Cell Res Ther 2:46. 2011..One of the key issues for clinical-grade iPSC derivation is the accessibility of donor cells used for reprogramming... 
Patient-centred treatments for type 2 diabetesYogish C Kudva
Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, MN 55905, USA
Lancet 371:1047-8. 2008- "Diabetic mastopathy," or sclerosing lymphocytic lobulitis, is strongly associated with type 1 diabetesYogish C Kudva
Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, Minnesota 55905 0001, USA
Diabetes Care 25:121-6. 2002..To demonstrate the strong association of diabetic mastopathy or sclerosing lymphocytic lobulitis with type 1 diabetes mellitus by studying appropriate control groups and to describe risk factors and natural history of the disorder... - Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetesYogish C Kudva
Division of Endocrinology, Mayo Clinic, Rochester, Minnesota 55905, USA
Diabetes Care 28:10-4. 2005..We conducted a randomized crossover design clinical trial to compare glargine with ultralente insulin as a basal insulin in type 1 diabetes... - Mastopathy and diabetesYogish C Kudva
Division of Endocrinology and Metabolism, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
Curr Diab Rep 3:56-9. 2003..It may be associated with retinopathy and neuropathy, but more research is needed to verify this association. The etiopathogenesis is unknown and the disorder does not seem to predispose to breast carcinoma or lymphoma... - Accelerated diabetes in rat insulin promoter-tumor necrosis factor-alpha transgenic nonobese diabetic mice lacking major histocompatibility class II moleculesGovindarajan Rajagopalan
Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905, USA
Diabetes 52:342-7. 2003..We also show for the first time that diabetes in NOD.RIP-TNF mice can occur independent of inheritance of NOD-derived idd1... - Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulinYogish C Kudva
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
Endocr Pract 13:244-50. 2007..To evaluate glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes receiving multiple daily insulin injections during glargine and Ultralente use as basal insulin in a clinical trial... - Distinct local immunogenic stimuli dictate differential requirements for CD4+ and CD8+ T cell subsets in the pathogenesis of spontaneous autoimmune diabetesGovindarajan Rajagopalan
Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Autoimmunity 40:489-96. 2007..Thus, the relative roles of CD4+ or CD8+T cells in the pathogenesis of T1D are possibly determined by the local inflammatory stimuli... - IL-10-deficiency unmasks unique immune system defects and reveals differential regulation of organ-specific autoimmunity in non-obese diabetic miceGovindarajan Rajagopalan
Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA
Cytokine 34:85-95. 2006..This was accompanied by a heightened systemic inflammatory cytokine response and mortality following in vivo challenge with a toll-like receptor 9 agonist, CpG-containing DNA... 
Chronic care model and shared care in diabetes: randomized trial of an electronic decision support systemSteven A Smith
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 83:747-57. 2008..To assess the effect of a specialist telemedicine intervention for improving diabetes care using the chronic care model (CCM)...- Long-term benefits of pancreas transplantationPatrick G Dean
Division of Transplant Surgery, Department of Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Curr Opin Organ Transplant 13:85-90. 2008..With more recipients enjoying normoglycemia for longer periods of time, the opportunity to study more closely the effects of pancreas transplantation has arisen. This review will focus on these long-term benefits... - Autoimmune diabetes in HLA-DR3/DQ8 transgenic mice expressing the co-stimulatory molecule B7-1 in the beta cells of islets of LangerhansGovindarajan Rajagopalan
Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
Int Immunol 15:1035-44. 2003..In conclusion, this study confirmed the diabetogenic potential of HLA-DQ8 and established the role of HLA-DR3 in the pathogenesis of T1D... - Modulation of insulitis and type 1 diabetes by transgenic HLA-DR3 and DQ8 in NOD mice lacking endogenous MHC class IIYogish C Kudva
Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, MN, USA
Hum Immunol 63:987-99. 2002..In conclusion, transgenic expression of HLA-DR3 and -DQ8 associated with predisposition to type 1 diabetes alone is not sufficient to induce spontaneous diabetes in NOD mice lacking endogenous class II molecules... - Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injectionsMitra M Fatourechi
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
J Clin Endocrinol Metab 94:729-40. 2009..Hypoglycemia limits the efficacy of intensive insulin therapy. The extent to which continuous insulin infusion (CSII) overcomes this limitation is unclear... - Telecare for patients with type 1 diabetes and inadequate glycemic control: a randomized controlled trial and meta-analysisVictor M Montori
Division of Endocrinology, Diabetes, Metabolism, Nutrition, and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Diabetes Care 27:1088-94. 2004..CONCLUSIONS: Telecare is associated with small effects on glycemic control in patients with type 1 diabetes on intensive insulin therapy but with inadequate glycemic control... - Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis?Mae Sheikh-Ali
Division of Endocrinology, Diabetes, Nutrition, and Metabolism, Mayo Clinic, Rochester, Minnesota 55905, USA
Diabetes Care 31:643-7. 2008..The present study was undertaken to determine whether quantitative measurement of a ketone body anion could be used to diagnose DKA... - Melanin concentrating hormone is a novel regulator of islet function and growthPavlos Pissios
Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Diabetes 56:311-9. 2007..Together, these data provide novel evidence for an autocrine role for MCH in the regulation of beta-cell mass dynamics and in islet secretory function and suggest that MCH is part of a hypothalamic-islet (pancreatic) axis... - Insulin sensitizersFarhad Zangeneh
Division of Endocrinology, Diabetes, Metabolism, Nutrition and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 78:471-9. 2003..We discuss safety issues of these agents, their potential use in preventing onset and progression of diabetes, and their use in other related metabolic conditions such as polycystic ovary syndrome... - Autoimmunity in HLA-DQ8 transgenic mice expressing granulocyte/macrophage-colony stimulating factor in the beta cells of islets of LangerhansGovindarajan Rajagopalan
Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Autoimmunity 40:169-79. 2007.... - Immunotherapeutic agents in type 1 diabetes: a systematic review and meta-analysis of randomized trialsGunjan Y Gandhi
Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Clin Endocrinol (Oxf) 69:244-52. 2008..We conducted a systematic review and meta-analysis to determine the efficacy of nonantigen-based immunotherapeutic approaches for preservation of beta-cell function in patients with type 1 diabetes... - Celiac disease in type 1 diabetes mellitus in a North American community: prevalence, serologic screening, and clinical featuresFarid H Mahmud
From the Division of Pediatric Endocrinology and Metabolism, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Mayo Clin Proc 80:1429-34. 2005..CONCLUSIONS: Celiac disease Is not rare In North American patients with type 1 diabetes, and most CD-positive diabetic patients are asymptomatic Irrespective of age at screening... - Posttransplantation diabetes: a systematic review of the literatureVictor M Montori
Division of Endocrinology, Diabetes, Metabolism, Nutrition, and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Diabetes Care 25:583-92. 2002..Randomized trials are needed to evaluate the use of oral glucose-lowering agents in transplant recipients, paying particular attention to interactions with immunosuppressive drugs... - Epidemiology of infections requiring hospitalization during long-term follow-up of pancreas transplantationNassir Rostambeigi
Division of Endocrinology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
Transplantation 89:1126-33. 2010..Bladder drainage increases infection risk and low ALC partially predicts episodes. Limitations include retrospective design, unequal composition of PT groups, and lack of data between kidney and PT for PAK... - Pancreas-after-kidney transplantation: an increasingly attractive alternative to simultaneous pancreas-kidney transplantationTimothy S Larson
Department of Internal Medicine, Division of Nephrology, Mayo Clinic, Rochester, MN 559805, USA
Transplantation 77:838-43. 2004..Although the shorter waiting time and the ability to use living-donor kidneys make PAK an increasingly attractive alternative to SPK transplantation, its effect on renal allograft function deserves further attention... - Potentially important contribution of dextrose used as diluent to hyperglycemia in hospitalized patientsBryan J Krajicek
Diabetes Care 28:981-2. 2005 - Strategies to improve outcomes after renal transplantationVictor M Montori
N Engl J Med 346:2089-92; author reply 2089-92. 2002 - Caring advice. Interview by Carol TruemanYogish C Kudva
Caring 24:37-41. 2005 - Residual dysphasia after severe hypoglycemia in a patient with immune-mediated primary adrenal insufficiency and type 1 diabetes mellitus: case report and systematic review of the literatureFatima Ajaz
Department of Internal Medicine, University of Connecticut, Farmington, Connecticut, USA
Endocr Pract 13:384-8. 2007....
Research Grants
- Integrated approaches to close the loop in type 1 diabetesYOGISH C contact KUDVA; Fiscal Year: 2010..We believe that information obtained from our research will result in the development of a first generation endocrine artificial pancreas. ..